Accendra Health (NYSE:ACH) Stock Bumped Up to “Hold” by Zacks Research

Zacks Research upgraded shares of Accendra Health (NYSE:ACH) from a strong sell rating to a hold rating in a research note published on Tuesday morning,Zacks reports.

A number of other brokerages also recently issued reports on ACH. UBS Group reduced their price objective on shares of Accendra Health from $4.50 to $1.50 and set a “neutral” rating for the company in a research report on Thursday, August 13th. Weiss Ratings reissued a “sell (e+)” rating on shares of Accendra Health in a research report on Tuesday. Robert W. Baird lowered Accendra Health from an “outperform” rating to a “neutral” rating and set a $1.50 price objective for the company. in a report on Tuesday, August 11th. Finally, Citigroup cut Accendra Health from a “buy” rating to a “neutral” rating and reduced their price target for the company from $4.50 to $1.50 in a research report on Monday, August 10th. Four equities research analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Reduce” and an average price target of $1.50.

Accendra Health Price Performance

ACH opened at $0.28 on Tuesday. Accendra Health has a 1 year low of $0.19 and a 1 year high of $4.69. The company has a market capitalization of $21.17 million, a price-to-earnings ratio of -0.07 and a beta of 1.60. The firm’s fifty day moving average price is $0.66 and its two-hundred day moving average price is $2.14.

Accendra Health (NYSE:ACH) last announced its earnings results on Monday, August 10th. The company reported ($0.19) EPS for the quarter, missing the consensus estimate of ($0.13) by ($0.06). Accendra Health had a negative net margin of 11.41% and a negative return on equity of 4.02%. The firm had revenue of $613.23 million during the quarter. As a group, equities analysts anticipate that Accendra Health will post -0.03 EPS for the current year.

Hedge Funds Weigh In On Accendra Health

A number of hedge funds have recently added to or reduced their stakes in ACH. BlackRock Inc. purchased a new stake in shares of Accendra Health during the second quarter valued at $18,824,000. Bank of America Corp DE bought a new stake in Accendra Health in the 2nd quarter worth approximately $12,912,000. Dimensional Fund Advisors LP bought a new stake in Accendra Health in the 1st quarter worth approximately $5,943,000. Paradigm Capital Management Inc. NY bought a new stake in Accendra Health in the 2nd quarter worth approximately $8,676,000. Finally, Connor Clark & Lunn Investment Management Ltd. purchased a new stake in Accendra Health during the 2nd quarter valued at $4,408,000.

Accendra Health Company Profile

Accendra Health Inc is a nationwide provider of products, technology, and services that support health beyond the hospital by connecting patients, providers, and insurers. Through its brands, Apria and Byram Healthcare, the company delivers disposable medical supplies, integrated home healthcare equipment, and related services that help improve health outcomes and quality of life for individuals with chronic, complex, and acute health conditions. Its offerings span diabetes treatment, home respiratory therapy, and obstructive sleep apnea treatment, along with patient support services.